The pharmaceutical industry is experiencing steady growth due to surging healthcare demand worldwide, particularly with an aging population and the rising prevalence of chronic and rare diseases and regulatory initiatives. Moreover, pharma 4.0 is expected to bring about significant advancements and efficiencies in the industry.
Given the industry’s promising prospects, investors could consider snatching up fundamentally sound pharma stocks Bristol-Myers Squibb Company (BMY), Spero Therapeutics, Inc. (SPRO), and OptiNose, Inc. (OPTN) for steady gains during market dips.
